Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$2.66 USD
-0.11 (-3.97%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $2.66 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.66 USD
-0.11 (-3.97%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $2.66 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Zacks News
What's in the Cards for Adverum (ADVM) This Earnings Season?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.
Editas Medicine (EDIT) Looks Good: Stock Moves Up 11.3%
by Zacks Equity Research
Editas Medicine, Inc. (EDIT) moved big moved last session, as its shares rose over 11% on the day.
What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?
by Zacks Equity Research
Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.
Why Editas Medicine (EDIT) Might Surprise This Earnings Season
by Zacks Equity Research
Investors are always looking for stocks that are poised to beat at earnings season and Editas Medicine, Inc. (EDIT) may be one such company.
Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?
by Zacks Equity Research
Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.
4 Drug Stocks Poised to Beat this Earnings Season
by Zacks Equity Research
M&A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017.
What's in Store for Immune Design (IMDZ) Stock in Q1 Earnings?
by Zacks Equity Research
Immune Design Corp (IMDZ) is expected to report first-quarter 2017 results on May 9.
What's in Store for BioDelivery (BDSI) this Earnings Season?
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) is expected to report first-quarter 2017 results later this month. Last quarter, the company???s loss was wider than expected.
Teva Pharmaceutical (TEVA) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to report first-quarter 2017 earnings on May 11
Is Horizon Pharma (HZNP) Poised for a Beat in Q1 Earnings?
by Zacks Equity Research
Horizon Pharma plc (HZNP) is scheduled to report first-quarter 2017 results before the opening bell on May 8.
What's in the Cards for Allergan (AGN) this Earnings Season?
by Zacks Equity Research
Allergan plc (AGN) will be reporting first-quarter 2017 earnings result on May 9, before the market opens.
Arena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store?
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) is expected to report first-quarter 2017 on May 9, after market closes.
Can Ligand (LGND) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report first-quarter 2017 results on May 9, after the market closes.
What to Expect from Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Epizyme, Inc. (EPZM) is scheduled to report first-quarter 2017 results on May 8, before the opening bell.
What's in Store for Adverum (ADVM) in Q1 Earnings?
by Zacks Equity Research
Adverum Biotechnologies, Inc (ADVM) is expected to report first-quarter 2017 results later this month.
What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report first-quarter 2017 results on May 11.
GW Pharmaceuticals (GWPH) Q2 Earnings: What to Expect?
by Zacks Equity Research
GW Pharmaceuticals plc (GWPH) is expected to report second-quarter fiscal 2017 results on May 4.
What's in the Cards for ACADIA (ACAD) this Earnings Season?
by Zacks Equity Research
ACADIA Pharmaceuticals Inc. (ACAD) is expected to report first-quarter 2017 results on May 4.
Agios Pharmaceuticals (AGIO) Q1 Earnings: What's in Store?
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report first-quarter results on May 4 before market open.
Allergan (AGN) and Editas Tie Up to Treat Eye Diseases
by Zacks Equity Research
Allergan plc's (AGN), and Editas Medicine, Inc. (EDIT), entered into a strategic research and development agreement.
Editas Medicine (EDIT) Shares March Higher, Can It Continue?
by Zacks Equity Research
Editas Medicine, Inc. (EDIT) has been on the move lately as the stock has risen by 6.6% in the past four weeks, and it is currently trading well above its 20-Day SMA